Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies

British Journal of Cancer

Volumn 112, Issue 3, 2015, Pages 413-418

  Arteaga, M F ^a   Mikesch, J H ^a   Fung, T K ^a   So, C W E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

acute promyelocytic leukaemia pathogenesis; ATRA; epigenetics; histone demethylase; histone methylation; PHF8; target therapy

Indexed keywords

HISTONE DEMETHYLASE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

CANCER RESISTANCE; DNA METHYLATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; TREATMENT RESPONSE; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MOLECULAR TARGETED THERAPY; OXIDES; RECEPTORS, RETINOIC ACID; TREATMENT OUTCOME; TRETINOIN;

EID: 84922267520     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.374     Document Type: Review

References (61)

1. Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117(22): 5795-5802.
2. Arteaga MF, Mikesch JH, Qiu J, Christensen J, Helin K, Kogan SC, Dong S So CW (2013) The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell 23(3): 376-389.
3. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11(10): 726-734.
4. Botrugno OA, Santoro F, Minucci S (2009) Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280(2): 134-144.
5. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, Otte AP Pradel J, Muchardt C, Sieweke M, Duprez E (2009) The PRC1 polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23(10): 1195-1206.
6. Breccia M, Lo-Coco F (2012) Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 13(7): 1031-1043.
7. Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG Minucci S (2006) Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26(4): 1288-1296.
8. Chen SJ, Chen Z (2013) Targeting agents alone to cure acute promyelocytic leukemia. N Engl J Med 369(2): 186-187.
9. Cheung N, So CW (2011) Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett 585(13): 2100-2111.
10. Chim CS, Liang R, Tam CY, Kwong YL (2001) Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 19(7): 2033-2040.
11. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C Miller Jr WH (2002) Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 100(7): 2586-2596.
12. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295(5557): 1079-1082.
13. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I (2005) A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123(5): 819-831.
14. Feng W, Yonezawa M, Ye J, Jenuwein T, Grummt I (2010) PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol 17(4): 445-450.
15. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1): 13-27.
16. Fortschegger K, de Graaf P, Outchkourov NS, van Schaik FM, Timmers HT Shiekhattar R (2010) PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol Cell Biol 30(13): 3286-3298.
17. Fung TK, So CW (2013) Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget 4(8): 1128-1129.
18. Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W (2012) Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 120(10): 2098-2108.
19. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T (2011) Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 118(6): 1600-1609.
20. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptoralpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669): 815-818.
21. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108(9): 1321-1330.
22. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, Nieselt K Zschunke M, Disselhoff C, Agrawal S, Isken F, Tidow N, Berdel WE Serve H, Muller-Tidow C (2008) Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 111(5): 2887-2895.
23. Kleine-Kohlbrecher D, Christensen J, Vandamme J, Abarrategui I, Bak M Tommerup N, Shi X, Gozani O, Rappsilber J, Salcini AE, Helin K (2010) A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell 38(2): 165-178.
24. Kwok C, Zeisig BB, Dong S, So CW (2006) Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell 9(2): 95-108.
25. Lallemand-Breitenbach V, Zhu J, Chen Z, de The H (2012) Curing APL through PML/RARA degradation by As2O3. Trends Mol Med 18(1): 36-42.
26. Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R Minucci S, de The H (2012) Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26(7): 1630-1637.
27. Lin RJ, Evans RM (2000) Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5(5): 821-830.
28. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391(6669): 811-814.
29. Liu W, Tanasa B, Tyurina OV, Zhou TY, Gassmann R, Liu WT, Ohgi KA Benner C, Garcia-Bassets I, Aggarwal AK, Desai A, Dorrestein PC, Glass CK, Rosenfeld MG (2010) PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature 466(7305): 508-512.
30. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U. Gruppo Italiano Malattie Ematologiche dellAdulto, the German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2): 111-121.
31. Loenarz C, Ge W, Coleman ML, Rose NR, Cooper CD, Klose RJ, Ratcliffe PJ Schofield CJ (2010) PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilon-dimethyl lysine demethylase. Hum Mol Genet 19(2): 217-222.
32. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F Altucci L, Stunnenberg HG (2010) PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17(2): 173-185.
33. McNamara S, Wang H, Hanna N, Miller Jr WH (2008) Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol 28(6): 2066-2077.
34. Mikesch JH, Gronemeyer H, So CW (2010) Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: emerging opportunity and challenge. Cancer Cell 17(2): 112-114.
35. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C Pelicci PG (2000) Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5(5): 811-820.
36. Pelosi A, Careccia S, Lulli V, Romania P, Marziali G, Testa U, Lavorgna S Lo-Coco F, Petti MC, Calabretta B, Levrero M, Piaggio G, Rizzo MG (2012) miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene 32(31): 3648-3654.
37. Petrie K, Prodromou N, Zelent A (2007) Histone deacetylase inhibitors in APL and beyond. Curr Top Microbiol Immunol 313: 157-203.
38. Qi HH, Sarkissian M, Hu GQ, Wang Z, Bhattacharjee A, Gordon DB Gonzales M, Lan F, Ongusaha PP, Huarte M, Yaghi NK, Lim H Garcia BA, Brizuela L, Zhao K, Roberts TM, Shi Y (2010) Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature 466(7305): 503-507.
39. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI Leiva M, Ablain J, Ambardekar C, McConnell MJ, Dick JE, Licht JD (2009) Comprehensive genomic screens identify a role for PLZFRARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 114(27): 5499-5511.
40. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG Chiocca S, Johnstone RW, Minucci S (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121(17): 3459-3468.
41. Sanz MA, Lo-Coco F (2011) Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 29(5): 495-503.
42. Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW Maurin T, Mari B, Barbry P, Vallar L, Friederich E, Arar K, Cassinat B Chomienne C, Lecellier CH (2009) Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 113(2): 412-421.
43. Schoofs T, Muller-Tidow C (2011) DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev 37(Suppl 1): S13-S18.
44. Schoofs T, Rohde C, Hebestreit K, Klein HU, Gollner S, Schulze I, Lerdrup M Dietrich N, Agrawal-Singh S, Witten A, Stoll M, Lengfelder E Hofmann WK, Schlenke P, Buchner T, Hansen K, Berdel WE Rosenbauer F, Dugas M, Muller-Tidow C (2013) DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood 121(1): 178-187.
45. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H Wang ZY, Chen SJ, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101(15): 5328-5335.
46. Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, Barnes J, Wilson AJ Taskesen E, Delwel R, Gil J, Van Lohuizen M, So CW (2011) Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 8(6): 649-662.
47. Soncini M, Santoro F, Gutierrez A, Frige G, Romanenghi M, Botrugno OA Pallavicini I, Pelicci P, Di Croce L, Minucci S (2013) The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta 1832(1): 114-120.
48. Spicuglia S, Vincent-Fabert C, Benoukraf T, Tiberi G, Saurin AJ Zacarias-Cabeza J, Grimwade D, Mills K, Calmels B, Bertucci F Sieweke M, Ferrier P, Duprez E (2011) Characterisation of genome-wide PLZF/RARA target genes. PLoS One 6(9): e24176.
49. Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, Silletto A Galimi F, Le Beau MM, Evans RM, Kogan SC (2006) Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell 9(2): 81-94.
50. Subramanyam D, Belair CD, Barry-Holson KQ, Lin H, Kogan SC, Passegue E Blelloch R (2010) PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res 70(21): 8792-8801.
51. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M (2006) Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107(4): 1546-1554.
52. Teofili L, Martini M, Luongo M, Diverio D, Capelli G, Breccia M, Lo Coco F Leone G, Larocca LM (2003) Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 17(5): 919-924.
53. Tomita A, Kiyoi H, Naoe T (2013) Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol 97(6): 717-725.
54. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E Nomdedeu JF, Jenuwein T, Pelicci PG, Minucci S, Fuks F, Helin K Di Croce L (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11(6): 513-525.
55. Wang K, Wang P, Shi J, Zhu X, He M, Jia X, Yang X, Qiu F, Jin W, Qian M Fang H, Mi J, Xiao H, Minden M, Du Y, Chen Z, Zhang J (2010) PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 17(2): 186-197.
56. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111(5): 2505-2515.
57. Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW (2012) SnapShot: acute myeloid leukemia. Cancer Cell 22(5): 698-698 e1.
58. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S So CW (2007) Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 12(1): 36-51.
59. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD (2001) Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 20(49): 7186-7203.
60. Zhang H, Luo XQ, Feng DD, Zhang XJ, Wu J, Zheng YS, Chen X, Xu L Chen YQ (2011) Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 10: 108.
61. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, Berthier C Kamashev D, Zhou J, Vitoux D, Lavau C, de The H (2007) RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12(1): 23-35.